Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31186745 | 0.84 | CA2 (0.48) | HTTCA2CYP1A2CYP3A4 | |
| SCHEMBL21184718 | 0.80 | CA2 (0.56) | HTTCA2LMNAKDM4ENFKB1 | |
| SCHEMBL31186754 | 0.79 | ALDH1A1 (0.46) | HTTCA2LMNAALDH1A1 | |
| SCHEMBL13681510 | 0.79 | SIRT1 (0.40) | HTTCA2LMNATDP1KDM4E | |
| SCHEMBL29622033 | 0.79 | HTT (0.40) | HTTCA2LMNAKDM4ECYP3A4 | |
| SCHEMBL1258850 | 0.79 | AKR1B1 (0.46) | HTTCA2LMNATDP1KDM4E | |
| SCHEMBL5215140 | 0.79 | HTT (0.47) | HTTCA2CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL1258849 | 0.79 | HSP90AB1 (0.38) | LMNACNR1HSP90AB1ALDH1A1 | |
| SCHEMBL10864964 | 0.79 | POLB (0.38) | LMNACNR1CYP3A4HSP90AB1ALDH1A1 | |
| SCHEMBL2702346 | 0.78 | CA2 (0.52) | HTTCA2LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585861-B2 | HIV replication inhibitors; for (multi)drug resistant HIV infection | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-08 | — | — | US | disclosed |
| EP-1902717-A2 | Vasopressin antagonist and oxytocin antagonist | Otsuka Pharmaceutical Company, Limited (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-0620003-B1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMA CO LTD (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | BMO BANK N.A., AS ADMINISTRATIVE AGENT | 2007-02-15 | — | — | US | disclosed |
| US-5753644-A | Vasopressin antagonist and oxytocin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5622947-A | VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0514667-B1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMA CO LTD (JP) | 1995-08-09 | — | — | EP | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5244898-A | Vasopressin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0514667-A1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037811-A1 | HIV replication inhibitors; for (multi)drug resistant HIV infection | REV1, CCNI, MCM6 | HTT 3778/4885CA2 4811/4885LMNA 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.